This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Alexion Pharmaceuticals, Inc.
Drug Names(s): eculizumab, 5G1.1
Description: BioMedTracker has separate drug profiles for Eculizumab. Please also see Eculizumab for asthma and dry AMD here.
Eculizumab is a humanized monoclonal antibody that targets the C5 component of complement. It is a construct similar to Alexion's lead drug, pexelizumab.
Deal Structure: Alexion contracted with Lonza to manufacture Eculizumab in January 2003.
In February 2008, Alexion agreed to acquire from Oklahoma Medical Research Foundation (OMRF) all rights to certain patents related to complement-inhibition technology. Alexion Pharmaceuticals Alexion will pay OMRF $10 million to acquire all rights and interests to the patents, in various amounts to be remitted in 2008 and the first half of 2009. No further amounts, including royalties, will be owed to OMRF in respect of sales of Soliris or other use of the OMRF patents.
On an undisclosed date, DRI Capital purchased royalties relating to the sales of Soliris for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. As a result of this transaction, DRI Capital, through its managed private equity funds, owns royalty entitlements for this drug for an undisclosed rate.
Partners: Lonza Group Ltd. DRI Capital Inc.
Additional information available to subscribers only: